, Volume 78, Issue 7, pp 759–759 | Cite as

Correction to: Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers


1 Correction to: Drugs  https://doi.org/10.1007/s40265-018-0903-9

An Online First version of this article was made available online at http://link.springer.com/journal/40265/onlineFirst/page/1 on 16 April 2018. Errors were subsequently identified in the article, and the following corrections should be noted:
  • Rewording in main text

    Section 1, Introduction, paragraph 3, line 1: The following line, which previously read:

    “Apatinib [AiTan™ (China); Rivoceranib® (global)] is a”

    Should read:

    “Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a”

The original article has been updated.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations